Patients with locally advanced, unresectable (not able to be surgically removed), stage 3 non–small cell lung cancer (NSCLC) with an EGFR mutation ...

Neoadjuvant (primary cancer treatment) Opdivo (nivolumab) plus Yervoy (ipilimumab) followed by therapeutic lymph node dissection (surgical removal of the ...

Enhertu (fam-trastuzumab deruxtecan-nxki; Enhertu) improved progression-free survival (PFS) over chemotherapy in pretreated patients with hormone receptor ...

Presurgical treatment with paclitaxel, Herceptin (trastuzumab) and Perjeta (pertuzumab) led to a clearance of circulating tumor DNA (ctDNA; cancer DNA ...

We’ve enlisted a few of our research experts to help guide you through some of the most important announcements at the world’s biggest cancer ...

Patients with relapsed/refractory multiple myeloma tended to live longer without their disease worsening (progression-free survival; PFS) when treated with ...

Perioperative chemotherapy (treatment around the time of surgery) with chemotherapies demonstrated survival benefits, compared with neoadjuvant ...

Rybrevant (amivantamab) plus Leclaza (lazertinib) led to promising outcomes in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) that ...

Tafinlar (dabrafenib) plus Mekinist (trametinib) continued to be efficacious in the postsurgical treatment of patients with stage 3 melanoma, according to ...

A new saliva test for identifying men at high risk of prostate cancer could help find more cases of the disease earlier, when doctors have a better ...